334 related articles for article (PubMed ID: 17174468)
1. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade.
Alty JE; Monaghan TM; Bamford JM
Clin Neurol Neurosurg; 2007 Apr; 109(3):279-81. PubMed ID: 17174468
[TBL] [Abstract][Full Text] [Related]
2. [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].
van Laar JA; Jamnitski A; Baarsma GS; van Daele PL; van Hagen PM
Ned Tijdschr Geneeskd; 2006 Apr; 150(13):705-9. PubMed ID: 16623340
[TBL] [Abstract][Full Text] [Related]
3. A case of mucocutaneous Behçet's disease responding to etanercept.
Sommer A; Altmeyer P; Kreuter A
J Am Acad Dermatol; 2005 Apr; 52(4):717-9. PubMed ID: 15793540
[No Abstract] [Full Text] [Related]
4. [The treatment of recurrent uveitis with TNF-alpha inhibitors].
Falappone PC; Iannone F; Scioscia C; Grattagliano V; Covelli M; Lapadula G
Reumatismo; 2004; 56(3):185-9. PubMed ID: 15470524
[TBL] [Abstract][Full Text] [Related]
5. Behçet's syndrome: from aetiology to treatment.
Powell RJ
Adv Exp Med Biol; 2003; 528():481-6. PubMed ID: 12918749
[No Abstract] [Full Text] [Related]
6. Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model.
Choi B; Hwang Y; Kwon HJ; Lee ES; Park KS; Bang D; Lee S; Sohn S
J Dermatol Sci; 2008 Nov; 52(2):87-97. PubMed ID: 18585901
[TBL] [Abstract][Full Text] [Related]
7. Anti-TNF therapy in the management of Behcet's disease--review and basis for recommendations.
Sfikakis PP; Markomichelakis N; Alpsoy E; Assaad-Khalil S; Bodaghi B; Gul A; Ohno S; Pipitone N; Schirmer M; Stanford M; Wechsler B; Zouboulis C; Kaklamanis P; Yazici H
Rheumatology (Oxford); 2007 May; 46(5):736-41. PubMed ID: 17403712
[No Abstract] [Full Text] [Related]
8. Effect of infliximab in progressive neuro-Behçet's syndrome.
Kikuchi H; Aramaki K; Hirohata S
J Neurol Sci; 2008 Sep; 272(1-2):99-105. PubMed ID: 18550081
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of long-standing neuro-Behçet's disease with infliximab.
Sarwar H; McGrath H; Espinoza LR
J Rheumatol; 2005 Jan; 32(1):181-3. PubMed ID: 15630746
[TBL] [Abstract][Full Text] [Related]
10. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.
Melikoglu M; Fresko I; Mat C; Ozyazgan Y; Gogus F; Yurdakul S; Hamuryudan V; Yazici H
J Rheumatol; 2005 Jan; 32(1):98-105. PubMed ID: 15630733
[TBL] [Abstract][Full Text] [Related]
11. The utility of tumour necrosis factor blockade in orphan diseases.
Keystone EC
Ann Rheum Dis; 2004 Nov; 63 Suppl 2(Suppl 2):ii79-ii83. PubMed ID: 15479879
[TBL] [Abstract][Full Text] [Related]
12. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNFalpha function with Etanercept in mdx mice.
Hodgetts S; Radley H; Davies M; Grounds MD
Neuromuscul Disord; 2006 Oct; 16(9-10):591-602. PubMed ID: 16935507
[TBL] [Abstract][Full Text] [Related]
13. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Suzuki K; Tanaka Y
Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
[No Abstract] [Full Text] [Related]
14. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
Gerloni V; Pontikaki I; Gattinara M; Fantini F
Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
[TBL] [Abstract][Full Text] [Related]
15. Lack of efficacy of etanercept in Sjögren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation.
Moutsopoulos NM; Katsifis GE; Angelov N; Leakan RA; Sankar V; Pillemer S; Wahl SM
Ann Rheum Dis; 2008 Oct; 67(10):1437-43. PubMed ID: 18198195
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of etanercept in the treatment of a patient with Behçet's disease.
Curigliano V; Giovinale M; Fonnesu C; Cerquaglia C; Verrecchia E; Turco S; Manganelli C; Manna R
Clin Rheumatol; 2008 Jul; 27(7):933-6. PubMed ID: 18330611
[TBL] [Abstract][Full Text] [Related]
17. A young girl with refractory intestinal Behçet's disease: a case report and review of literatures on pediatric cases who received an anti-tumor necrosis factor agent.
Watanabe S; Aizawa-Yashiro T; Tsuruga K; Kinjo M; Ito E; Tanaka H
Rheumatol Int; 2013 Dec; 33(12):3105-8. PubMed ID: 23266507
[TBL] [Abstract][Full Text] [Related]
18. Successful use of infliximab following a failed course of etanercept in a pediatric patient.
Farnsworth NN; George SJ; Hsu S
Dermatol Online J; 2005 Dec; 11(3):11. PubMed ID: 16409907
[No Abstract] [Full Text] [Related]
19. Etanercept, a tumour necrosis factor alpha receptor antagonist, and methotrexate in acute sensorineural hearing loss.
Street I; Jobanputra P; Proops DW
J Laryngol Otol; 2006 Dec; 120(12):1064-6. PubMed ID: 17040588
[TBL] [Abstract][Full Text] [Related]
20. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.
Benitah NR; Sobrin L; Papaliodis GN
Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
